
Sign up to save your podcasts
Or


Send us a text
Summary: The off-label use of naltrexone for chronic pain and inflammatory conditions is built upon observing patients being weaned from high dose naltrexone for alcohol abuse disorder, as well as its experimental use in boosting the immune system of HIV patients in the 1980s. Though the long-term use of LDN for chronic pain and the other inflammatory conditions has not been established, this unique mechanism of action may, in the future, provide another proven option for those in need. Or will it? We are in the process of discovery.
Topics:
· Low Dose Naltrexone Potential Uses 02:00
· Opioid Antagonists Naloxone and Naltrexone
· Receptor Interactions: Affinity/Intrinsic Activity/Dissociation. 04:15
· Naloxone & Naltrexone Chemistry
· Antabuse 08:20
· Fooling the Body – Negative Feeback Loop 11:30
· Microglial Cells Inhibition & Anti-inflammatory actions 12:50
· Applied Science of Medicine 14:00
· LDL Risks
· Quality of Life and Risk-Benefit 17:45
Questions and comments to [email protected]
By Donald Schoeff R.Ph.3.7
33 ratings
Send us a text
Summary: The off-label use of naltrexone for chronic pain and inflammatory conditions is built upon observing patients being weaned from high dose naltrexone for alcohol abuse disorder, as well as its experimental use in boosting the immune system of HIV patients in the 1980s. Though the long-term use of LDN for chronic pain and the other inflammatory conditions has not been established, this unique mechanism of action may, in the future, provide another proven option for those in need. Or will it? We are in the process of discovery.
Topics:
· Low Dose Naltrexone Potential Uses 02:00
· Opioid Antagonists Naloxone and Naltrexone
· Receptor Interactions: Affinity/Intrinsic Activity/Dissociation. 04:15
· Naloxone & Naltrexone Chemistry
· Antabuse 08:20
· Fooling the Body – Negative Feeback Loop 11:30
· Microglial Cells Inhibition & Anti-inflammatory actions 12:50
· Applied Science of Medicine 14:00
· LDL Risks
· Quality of Life and Risk-Benefit 17:45
Questions and comments to [email protected]

398 Listeners

27,693 Listeners

7 Listeners

14,268 Listeners

71 Listeners

20,212 Listeners

810 Listeners

37 Listeners

152 Listeners

378 Listeners

16 Listeners

0 Listeners

1,633 Listeners